Novo Nordisk ended its partnership with telehealth platform Hims & Hers, which offered Wegos at a discounted price of $499 or $599 per month for patients without insurance coverage.[1][3] The collaboration was announced in April and lasted only eight weeks.[2][4] Novo Nordisk accused Hims & Hers of illegally mass-mixing semaglutide, Wego's main active ingredient, under the guise of personalization.[1][5] Hims & Hers continues to sell compounded versions of semaglutide for $165 per month for patients who cannot tolerate Wegs due to side effects.[1][2] Wegovy is FDA-approved for weight loss in obese or overweight people with cardiovascular risk and to reduce the risk of cardiovascular events.[1][6] Novo Nordisk claims that such compounded drugs pose a risk to patient safety because they are not regulated by the FDA.[1][6] Hims & Hers responded that Novo Nordisk pushed to divert patients to Wegova regardless of clinical need.[1][4]